here are the details of a phase 3 AML trial by another company (with mixed results):
Actinium Pharmaceuticals has reported data from the Phase III SIERRA clinical trial of Iomab-B (Iodine-131-apamistamab) to treat patients with relapsed or refractory acute myeloid leukaemia (r/r AML).The randomised, multicentre, controlled trial enrolled 153 people aged 55 years and above with r/r AML and those who were heavily pre-treated and had high-risk characteristics such as a TP53 mutation.
The trial achieved a 22% disease control rate in the Iomab-B arm compared to 0% in the control arm. However overall survival endpoint was not met.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)